Comparative case series demonstrating disease modifying outcome with early ambroxol and enzyme replacement therapy in acute neuronopathic Gaucher disease

Abstract

Gaucher disease (GD) is an autosomal recessive inborn error of metabolism caused by acid β-glucocerebrosidase deficiency, which presents with a wide spectrum of clinical manifestations, ranging from perinatal-lethal to asymptomatic forms. GD type 1 (GD1) is the most frequent visceral form, whereas types 2 (GD2) and 3 (GD3) are associated with neurodegeneration (neuronopathic GD, nGD) and share overlapping manifestations, presenting as a continuum of neurological disease severity. Traditionally, GD2 is the most severe form and has a rapidly progressive course with death by age two to four years. Currently available treatments for GD include enzyme replacement therapy and substrate reduction therapy to ameliorate visceral, hematologic, and skeletal abnormalities; however, they are not efficacious for neurological manifestations. More recently, ambroxol has been suggested as an augmentative pharmacological chaperone for nGD. This comparative case series of three patients aims to demonstrate the impact of early neonatal initiation of ambroxol on neurological outcomes in our index case (Patient A), compared to two other patients (Patients B and C) who began ambroxol treatment at 10 months and 4 years and 1 month of age, respectively, after a later diagnosis of nGD with already established neurological symptoms. Patient A has normal age-related developmental milestones at four years, while Patients B and C have persistence of developmental delay albeit some forward progression in the former. Our report highlights that early neonatal diagnosis and ambroxol therapy could potentially be a game changer in mitigating disease progression in nGD by modifying the natural history of GD2. Expanding newborn screening will facilitate early diagnosis and significantly impact clinical outcomes and quality of life in GD patients with early initiation of treatment.

Keywords

Acute neuronopathic Gaucher disease / ambroxol / enzyme replacement therapy / disease-modifying outcome

References

[1] StirnemannJ,CamouF.A review of Gaucher disease pathophysiology, clinical presentation and treatments.Int J Mol Sci2017;18:441 PMCID:PMC5343975

[2] HughesDA. Gaucher disease. Seattle, WA: University of Washington; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1269/ [Last accessed on 18 Jun 2025]

[3] D'AmoreS,DonaldA.In-depth phenotyping for clinical stratification of Gaucher disease.Orphanet J Rare Dis2021;16:431 PMCID:PMC8515714

[4] ChenY,HettinghouseA.Molecular regulations and therapeutic targets of Gaucher disease.Cytokine Growth Factor Rev2018;41:65-74 PMCID:PMC8108120

[5] KotoY,LeeY.Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan.Mol Genet Metab2021;133:277-88

[6] ChristomanouH,LinkeRP.Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant.Biol Chem Hoppe Seyler1986;367:879-90

[7] HiraiwaM,KishimotoY,TsujiS.Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside.Arch Biochem Biophys1997;341:17-24

[8] ChinSJ.Prevalence of lysosomal storage disorders in Australia from 2009 to 2020.Lancet Reg Health2022;19:100344 PMCID:PMC8671750

[9] BurtonBK,HogansonGE.Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience.J Pediatr2017;190:130-5

[10] WassersteinMP,BaileySM.The New York pilot newborn screening program for lysosomal storage diseases: report of the First 65,000 Infants.Genet Med2019;21:631-40 PMCID:PMC6369014

[11] SavilleJT,ChinSJ,FullerM.Expanding the clinical utility of glucosylsphingosine for Gaucher disease.J Inherit Metab Dis2020;43:558-63

[12] DardisA,RozenfeldP.Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1.Orphanet J Rare Dis2022;17:442 PMCID:PMC9768924

[13] BartonNW,DambrosiaJM.Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease.N Engl J Med1991;324:1464-70

[14] AnderssonHC,KaplanP.Individualization of long-term enzyme replacement therapy for Gaucher disease.Genet Med2005;7:105-10

[15] CoutinhoMF,AlvesS.Less is more: substrate reduction therapy for lysosomal storage disorders.Int J Mol Sci2016;17:1065

[16] HicksJK,SwenJJ.Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.Clin Pharmacol Ther2017;102:37-44 PMCID:PMC5478479

[17] MistryPK,CharrowJ.Long-term effectiveness of eliglustat treatment: a real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.Am J Hematol2024;99:1500-10

[18] DaykinEC,SidranskyE.Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes.Mol Genet Metab2021;132:49-58 PMCID:PMC7884077

[19] JiangW,MaegawaGHB.Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease.J Hum Genet2020;65:345-9

[20] NaritaA,ItamuraS.Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study.Ann Clin Transl Neurol2016;3:200-15 PMCID:PMC4774255

[21] MaegawaGH,ButtnerJD.Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.J Biol Chem2009;284:23502-16 PMCID:PMC2749124

[22] AriesC,TiedeS.Promising effect of high dose ambroxol treatment on neurocognition and motor development in a patient with neuropathic Gaucher disease 2.Front Neurol2022;13:907317 PMCID:PMC9207411

[23] CharkhandB,NaritaA,Al-HertaniW.Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease.Mol Genet Metab Rep2019;20:100476 PMCID:PMC6713848

[24] ChuSY,HwuWL,ChienYH.Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant.Blood Cells Mol Dis2020;81:102402

[25] CianaG,PavanE.In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy.Mol Genet Metab Rep2020;25:100678 PMCID:PMC7691604

[26] KimYM,HeoSH.Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy.J Med Genet2020;57:124-31 PMCID:PMC7029246

[27] BelloAC.Early diagnosis of an infant with Gaucher's disease type 3. Case report.Blood2018;132:4950

[28] RamadžaDP,ŽigmanT.Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: a long-term outcome of two siblings.Eur J Paediatr Neurol2021;32:66-72

[29] HigashiK,KakuN.Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: a case report and literature review.Mol Genet Genomic Med2024;12:e2427 PMCID:PMC10980885

[30] PawlinskiL,Kiec-WilkB.The additive effect on the antiepileptic treatment of ambroxol in type 3 Gaucher patient. The early observation.Blood Cells Mol Dis2018;68:192-3

[31] IstaitiM,Becker-CohenM.Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data.Am J Hematol2021;96:545-51

[32] SchiffmannR,RolfsA.The definition of neuronopathic Gaucher disease.J Inherit Metab Dis2020;43:1056-9 PMCID:PMC7540563

[33] Migdalska-RichardsA,BezardE.Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.Ann Neurol2016;80:766-75 PMCID:PMC5132106

[34] LuanZ,HigakiK,SuzukiY.The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice.Brain Dev2013;35:317-22

[35] Migdalska-RichardsA,LiQ,SchapiraAHV.Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.Synapse2017;71:e21967 PMCID:PMC5485051

[36] Migdalska-RichardsA.The relationship between glucocerebrosidase mutations and Parkinson disease.J Neurochem2016;139 Suppl 1:77-90 PMCID:PMC5111601

[37] BabajaniG,MahuranDJ.Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.Mol Genet Metab2012;106:323-9 PMCID:PMC3425598

[38] Bendikov-BarI,FilocamoM.Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.Blood Cells Mol Dis2013;50:141-5 PMCID:PMC3547170

[39] Bendikov-BarI,FilocamoM.Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.Blood Cells Mol Dis2011;46:4-10

[40] IvanovaMM,TurgutA.Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines.Am J Transl Res2018;10:3750-61

[41] KopytovaAE,NikolaevMA.Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.Parkinsonism Relat Disord2021;84:112-21

[42] PantoomS,SchöllC.Mechanistic Insight into the mode of action of acid β-glucosidase enhancer ambroxol.Int J Mol Sci2022;23:3536 PMCID:PMC8998264

[43] ZimranA,ElsteinD.Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.Blood Cells Mol Dis2013;50:134-7

[44] DarlingA,GiraldoP.Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinsonian features and levodopa responsiveness.Parkinsonism Relat Disord2021;91:19-22

[45] SchuelerUH,KaneskiCR,SandhoffK.Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.J Inherit Metab Dis2004;27:649-58

[46] NairAB.A simple practice guide for dose conversion between animals and human.J Basic Clin Pharm2016;7:27-31 PMCID:PMC4804402

[47] IsmadiA,LiK,BhattacharyaK.Phenotypic spectrum of neonatal Gaucher disease.J Inherit Metab Dis2021;44:1-461

[48] GragnanielloV,GueraldiD.Light and shadows in newborn screening for lysosomal storage disorders: eight years of experience in northeast Italy.Int J Neonatal Screen2023;10:3

[49] HopkinsPV,KlugT,Raburn-MillerJ.Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.J Pediatr2015;166:172-7

[50] ChienYH,ChenPW.Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns.Orphanet J Rare Dis2020;15:38 PMCID:PMC6998831

[51] SawadaT,SugawaraK.Newborn screening for Gaucher disease in Japan.Mol Genet Metab Rep2022;31:100850 PMCID:PMC8866142

[52] KangL,GuX.Successful newborn screening for Gaucher disease using fluorometric assay in China.J Hum Genet2017;62:763-8 PMCID:PMC5537412